Fundraising Fox
/Companies
Sign in

Stablix

New York City, US · 36 employees on LinkedIn · 5 known investors

Find your way into Stablix

Sign up to see every warm intro you have to Stablix

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Stablix team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Stablix is a preclinical-stage biotechnology company developing small-molecule medicines based on targeted deubiquitination therapeutics (TDT), using heterobifunctional molecules that recruit deubiquitinases (DUBs) to target proteins to restore protein stability and normal function. It focuses on treatments for cancer, rare diseases, and immunological disorders.

BiotechDeep TechHealthtech

Founders & leadership

HCHenry Colecraft
Henry ColecraftCo-Founder & Chair of SAB
SKScott Kanner
Scott KannerCo-Founder & Scientific Advisor
ESEddine Saiah
Eddine SaiahCEO and PresidentEddine Saiah has over 20 years of drug discovery and development experience across pharmaceutical and biotech organizations, with a track record of advancing 15+ compounds to clinical development and co-authoring over 120 scientific publications and patents. He brings expertise across oncology, immunology, neuroscience, and rare diseases.

Investors · 5

Versant VenturesreportedSan Francisco · $250K – $5M

How we know: a partner's Signal profile · funding news · fiercebiotech.com · Not right? Tell us

Also in the syndicate · 3

Alexandria Real Estate EquitiesCormorant Asset ManagementEuclidean Capital

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Stablix do?
Stablix is a preclinical-stage biotechnology company developing small-molecule medicines based on targeted deubiquitination therapeutics (TDT), using heterobifunctional molecules that recruit deubiquitinases (DUBs) to target proteins to restore protein stability and normal function. It focuses on treatments for cancer, rare diseases, and immunological disorders.
Who founded Stablix?
Stablix was founded by Henry Colecraft, Scott Kanner.
Who are Stablix's investors?
Stablix's investors include New Enterprise Associates (NEA), Versant Ventures.
Where is Stablix headquartered?
Stablix is headquartered in New York City, US.